Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2026: 83% Year-Over-Year Growth in U.S. Sales and Major Growth in U.S. Commercial Reach to 21 States

      IceCure Medical Logo

      News provided by

      IceCure Medical

      Nov 18, 2026, 08:25 ET

      Share this article

      Share this article


      CAESAREA, Israel, Nov. 18, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today reported its financial and operating results as of and for the nine months ended September 30, 2026.

      Third Quarter 2026 Operational and Clinical Highlights

      • 83% Growth in U.S. Sales: U.S. sales of ProSense® and its cryoprobes doubled year over year during the first nine months of 2026 compared to the same period in 2025.
      • 26% Year-Over-Year Revenue Growth: Total revenues for the first nine months of 2026 increased to approximately $2.6 million, compared to $2.1 million in the corresponding period of 2025.
      • Expanded U.S. Commercial Reach: The Company's commercial presence expanded from 11 states in the third quarter of 2025 to 21 states in the third quarter of 2026.
      • Continued Progress in the ChoICE Study: The Company's post-marketing study (the "ChoICE" Study") evaluating ProSense® cryoablation for the local treatment of low-risk breast cancer launched the first clinical sites after Institutional Review Board ("IRB") approval at West Cancer Center & Research Institute (the "West Cancer Center") in Germantown, TN and Adventist Health Glendale in Glendale, CA.
      • International Commercial and Regulatory Progress: Received regulatory approval from China's National Medical Products Administration to market ProSense® as a Class III medical device and signed an exclusive distribution agreement for ProSense® cryoablation systems in the Netherlands.

      "We believe the first nine months of 2026 demonstrate the progress we made in translating our regulatory and clinical achievements into commercial growth, particularly in the United States. U.S. sales increased 83% year over year, while our commercial reach expanded from 11 to 21 states during the third quarter of 2026. At the same time, we are building the clinical foundation for broader adoption of ProSense® through the ChoICE Study. We believe these developments position us to continue driving physician adoption and expanding patient access to ProSense®," said Eyal Shamir, Chief Executive Officer of IceCure Medical.

      ChoICE Study Moving Forward:

      Subsequent to the end of the third quarter of 2026, IceCure announced additional progress in its ChoICE Study:

      • Three clinical sites joined the Company's study, including Legacy Health in Portland, Oregon.
      • The Company announced the enrollment of the first two patients in the ChoICE Study at two U.S. clinical sites: West Cancer Center in Tennessee and Adventist Health Glendale in California.
      • The Company announced the successful completion of the first ProSense® cryoablation treatment in the ChoICE Study. The first patient was treated at West Cancer Center in Germantown, Tennessee, by Dr. Richard E. Fine, MD, FACS.

      Additional Third Quarter of 2026 Successes:

      • Expanded U.S. Commercial Team: Strengthened the U.S. sales and marketing organization by adding dedicated professionals in key territories, including New York, Southern California and the Midwest, and Florida, as well as additional clinical support personnel to support physician training and adoption of ProSense®.
      • Participation in Leading Medical Events: Participated in key medical and industry events, including Aptitude Health's Targeted Medical Education ("TME") Take the Lead in Breast Cancer Fall Summit 2026 in New Orleans, LA and the 2026 European Society of Breast Imaging ("EUSOBI") Congress in Maastricht, Netherlands, engaging with leading breast cancer specialists and the broader medical community.
      • Strengthened Clinical Evidence: Highlighted two new peer-reviewed scientific publications supporting the role of cryoablation in breast cancer treatment de-escalation, including publications addressing early-stage breast cancer and axillary lymph node metastases.
      • Professional Recognition of Cryoablation: The Society of Interventional Oncology ("SIO") submitted a formal petition to the National Comprehensive Cancer Network ("NCCN") to include percutaneous cryoablation as a treatment option in its breast cancer guidelines, potentially broadening the range of treatment options available to eligible patients.

      Financial Results for the Nine Months Ended September 30, 2026

      Total revenues for the nine months ended September 30, 2026 increased approximately 26% to $2.6 million, compared to $2.1 million for the corresponding period in 2025.

      Gross profit for the nine months ended September 30, 2026 increased approximately 22% to $762,000, compared to $626,000 in the corresponding period of 2025.

      Research and development expenses for the nine months ended September 30, 2026 were $6.5 million, compared to $5.1 million in the corresponding period of 2025, primarily reflecting increased expenses related to the ChoICE Study and other clinical and development activities.

      Sales and marketing expenses were $3.6 million for the nine months ended September 30, 2026, compared to $3.0 million in the corresponding period of 2025, primarily reflecting the continued expansion of the Company's U.S. commercial activities.

      General and administrative expenses were $3.5 million for the nine months ended September 30, 2026, compared to $3.3 million in the corresponding period of 2025.

      Operating loss for the nine months ended September 30, 2026 was $12.9 million, compared to $10.8 million in the corresponding period of 2025.

      Net loss for the nine months ended September 30, 2026, was $12.9 million, compared to $10.8 million in the corresponding period of 2025.

      As of September 30, 2026, the Company's cash and cash equivalents totaled approximately $8.2 million, and shareholders' equity was approximately $8.7 million.

      Conference call & webcast info: 

      Wednesday, November 18, 2026, at 10:00 am EST
      US: 1-888-407-2553
      Israel/International: +972-3-918-0696
      A live webcast will be available at: https://www.veidan-conferenceing.com/icecure
      A recording of the webcast will be available at: https://ir.icecure-medical.com/

      About IceCure Medical

      IceCure Medical (NASDAQ: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, as a safe and effective minimally invasive option to surgical tumor removal, with the primary focus areas being breast, kidney, bone and lung cancer. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and Asia.

      ProSense® cryoablation became the first-and-only medical device cleared by the FDA for the local treatment of breast cancer in patients aged 70 years and older with biologically low-risk tumors ≤1.5 cm in size who are treated with adjuvant endocrine therapy, including patients who are not eligible for surgery.

      Forward Looking Statements

      This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. For example, the Company is using forward-looking statements when it discusses its belief that the first nine months of 2026 demonstrate the progress the Company has made in translating its regulatory and clinical achievements into commercial growth; that the ChoICE Study is building the clinical foundation for broader adoption of ProSense®; that the Company's developments position it to continue driving physician adoption and expanding patient access to ProSense®; the continued expansion of its U.S. commercial footprint, active installed base clinic support personnel and physician adoption; the addition of IRB-approved U.S. clinical sites for the CHoICE Study to support physician adoption; and the belief that professional recognition of cryoablation through the petition submitted by the SIO can potentially broaden the range of treatment options available to eligible patients. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC on March 17, 2026, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

      Investor Relations:

      Meir Peleg, CFO

      [email protected]

      +1-888-902-5716

      ICECURE MEDICAL LTD.


      CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION






      As of
      September 30,
      2026



      As of
      December 31,
      2025




      (Unaudited)







      U.S. dollars in thousands









      ASSETS







      CURRENT ASSETS







           Cash and cash equivalents



      8,220




      8,897


           Trade receivables



      391




      331


           Inventory



      2,578




      2,625


           Prepaid expenses and other receivables



      1,298




      752


      Total current assets



      12,487




      12,605











      NON-CURRENT ASSETS









           Right-of-use assets



      729




      239


           Property and equipment, net



      940




      993


           Long-term restricted deposits



      53




      51


      Total non-current assets



      1,722




      1,283


      TOTAL ASSETS



      14,209




      13,888











      LIABILITIES AND SHAREHOLDERS' EQUITY


















      CURRENT LIABILITIES









           Trade payables



      1,071




      863


           Lease liabilities



      255




      204


           Employees and employees related benefits



      3,024




      2,659


           Other current liabilities



      633




      1,098


      Total current liabilities



      4,983




      4,824











      NON-CURRENT LIABILITIES









           Long-term lease liabilities



      452




      13


      Total non-current liabilities



      452




      13











      SHAREHOLDERS' EQUITY









      Ordinary shares, No par value; Authorized 2,500,000,000 shares; Issued and
      outstanding: 5,563,265 shares and 2,437,410 shares as of September 30,
      2026 and December 31, 2025, respectively









           Additional paid-in capital



      142,205




      129,487


           Accumulated deficit



      (133,431)




      (120,436)


           Total shareholders' equity



      8,774




      9,051


           TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY



      14,209




      13,888


      ICECURE MEDICAL LTD.


      CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS






      Nine months ended
      September 30,




      2026



      2025




      U.S. dollars in thousands
      (except per share data)


      Revenues



      2,642




      2,100


      Cost of revenues



      1,880




      1,474


      Gross profit



      762




      626


      Research and development expenses



      6,557




      5,137


      Sales and marketing expenses



      3,669




      3,061


      General and administrative expenses



      3,527




      3,306


      Operating loss



      12,991




      10,878


      Finance expenses (income), net



      4




      (67)











      Net loss and comprehensive loss



      12,995




      10,811


      Basic and diluted net loss per share



      3.57




      5.4


      Weighted average number of shares outstanding used in
      computing basic and diluted loss per share



      3,637,322




      2,018,573


      ICECURE MEDICAL LTD.

      CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS




      Nine months ended
      September 30,




      2026



      2025





      U.S. dollars in
      thousands


      Cash flows from operating activities
















      Net loss


      (12,995)



      (10,811)



      Adjustments to reconcile net loss to net cash used in operating activities:










      Depreciation



      207




      224



      Share-based compensation



      687




      1,102



      Exchange rate changes in cash and cash equivalents and long-term restricted
      deposits



      (24)




      118



      Other finance cost



      -




      (34)



      Changes in assets and liabilities:










      Decrease (increase) in trade receivables



      (60)




      117



      Decrease (increase) in prepaid expenses and other receivables



      (546)




      145



      Decrease (increase) in inventory



      47




      (723)



      Decrease in right of use assets



      228




      251



      Increase (decrease) in trade payables



      208




      (81)



      Decrease in lease liabilities



      (227)




      (212)



      Increase in employees and employees related liabilities



      365




      595



      Decrease in other current liabilities



      (465)




      (246)



      Net cash used in operating activities



      (12,575)




      (9,555)













      Cash flows from investing activities










      Investment in short-term deposits



      -




      (5,000)



      Purchase of property and equipment



      (154)




      (31)



      Net cash used in investing activities



      (154)




      (5,031)













      Cash flows from financing activities:










      Proceeds from issuance of ordinary shares, warrants and pre-funded warrants, net
      of issuance costs



      12,020




      12,114



      Proceeds from exercise of warrants and pre-funded warrants



      10




      -



      Net cash provided by financing activities



      12,030




      12,114













      Decrease in cash and cash equivalents



      (699)




      (2,472)



      Cash and cash equivalents at beginning of the year



      8,897




      7,564



      Effect of exchange rate fluctuations on balances of cash and cash equivalents



      22




      (121)



      Cash and cash equivalents at end of period



      8,220




      4,971













      Non-cash activities










      Obtaining a right-of-use asset in exchange for a lease liability



      718




      41



      SOURCE IceCure Medical

      Modal title

      Also from this source

      IceCure Medical to Report Third Quarter 2026 Financial and Operating Results on November 18, 2026

      IceCure Medical to Report Third Quarter 2026 Financial and Operating Results on November 18, 2026

      IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...

      IceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP Portfolio

      IceCure Granted New Patent in China for Its Cryogenic System Connector, Expanding Its Global IP Portfolio

      IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Equipment

      Medical Equipment

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Computer & Electronics

      Computer & Electronics

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.